Paper:
The safety and efficacy of NeVa mechanical thrombectomy device in acute ischemic stroke: A systematic review and meta-analysisAuthors:
Mohammad Amin Habibi, Mohammad Sina Mirjnani, Saeed Kargar-Soleimanabad, Mohammad Taha Akbari Javar, Maryam Diyanati, Muhammad Hussain Ahmadvand, Inka K. Berglarf, Adam A. Dmytriw
Journal:
Journal of Clinical Neuroscience 2024
Background:
Recent favorable cohort studies on endovascular therapy for ischemic stroke have predominantly utilized NeVa thrombectomy (NeVa™) stent retrievers. We carried out a systematic review and meta-analysis to investigate the efficacy and safety of this second-generation stent retriever in acute ischemic stroke patients. Method: We conducted the study according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. The electronic databases of PubMed, Embase, and Scopus were searched until 26 November 2023 and was updated on August 1, 2024.
Methods:
The current study has been conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. The PRISMA checklist was shown in Supplementary Table S2. The International Prospective Register of Systematic Reviews (PROSPERO) has approved the study protocol using the code of CRD42024585494.
Results:
This meta-analysis systematically investigated 11 studies with a total of 805 patients suffering from ischemic stroke. The mean age of participants across the studies ranged from 65 to 77 years with a male preponderance of 50.16 %.
While ten studies reported on the etiology of strokes, some studies reported the risk factors such as hypertension, dyslipidemia, diabetes, history of coronary artery disease, and previous stroke.
The results of our study indicate that the all-hemorrhagic complications rate was 0.32 (95 %CI: 0.18–0.45), while the complete arterial recanalization rate was 0.76 [95 %CI: 0.49–1.04]. The overall recanalization rate was found to be 0.97 [95 %CI: 0.94–1.00]. Moreover, the postoperative hemorrhage rate was 0.28 [95 %CI: 0.14–0.41], while the repeated re-thrombosis rate was 0.01 [95 %CI: − 0.01–0.03]. Lastly, the vasospasm rate was calculated to be 0.09 [95 %CI: − 0.03–0.21].
Conclusion:
In summary, our findings indicate that NeVa™ is a safe option capable of achieving a high rate of recanalization and promoting functional independence. The rates of symptomatic ICH and mortality are comparable to those of standard stent retrievers. Therefore, it is essential to conduct future randomized controlled trials to thoroughly evaluate its clinical efficacy when compared to established reference treatments.
